NASDAQ: FOCLEdap Tms Sa Stock
$5.61+0.17 (+3.13%)
Updated Jul 20, 2026
FOCL Price
$5.61
Fair Value Price
N/A
Market Cap
$210.27M
52 Week Low
$1.21
52 Week High
$5.64
P/E
-5.75x
P/B
17.69x
P/S
1.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$87.98M
Earnings
-$35.93M
Gross Margin
43.4%
Operating Margin
-34.73%
Profit Margin
-41.8%
Debt to Equity
6.13
Operating Cash Flow
-$15M
Beta
0.42
Next Earnings
Aug 27, 2026
Ex-Dividend
N/A
Next Dividend
N/A
FOCL Overview
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FOCL's potential to beat the market
- FOCL doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Distribution
Industry Rating
A
FOCL
RankedUnranked of 5
RankedUnranked of 5
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $225.75 | A | |
| $86.20 | C | |
| $303.99 | C |
Be the first to know about important FOCL news, forecast changes, insider trades & much more!
FOCL News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FOCL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FOCL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FOCL is good value based on its book value relative to its share price (17.69x), compared to the US Medical Distribution industry average (159.7x)
P/B vs Industry Valuation
FOCL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FOCL due diligence checks available for Premium users.
Valuation
FOCL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.75x
Industry
25x
Market
11.71x
FOCL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
17.69x
Industry
159.7x
FOCL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FOCL's financial health
Profit margin
Revenue
$20.5M
Net Income
-$10.4M
Profit Margin
-51%
FOCL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FOCL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$82.8M
Liabilities
$71.2M
Debt to equity
6.13
FOCL's short-term assets ($59.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FOCL's short-term assets ($59.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FOCL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
FOCL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
-$866.7k
Financing
-$1.6M
FOCL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FOCL vs Medical Distribution Stocks
Edap Tms Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.